Editorial Commentary
Variability of relative cerebral blood volume measurements of recurrent glioma
Abstract
Primary central nervous system (CNS) tumors are a leading cause of death worldwide, with an incidence of 7.08 per 100,000 and an average of 15,944 deaths per year in the United States alone. The 5-year survival rate is 35.8% for all malignant CNS tumors, and only 6.8% for glioblastomas (1); thus, determining a method of monitoring effectiveness of treatment and recurrence is of utmost importance.